Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
Sergio Giralt,Karen K. Ballen,Douglas Rizzo,Andreas Bacigalupo,Mary M. Horowitz,Marcelo C. Pasquini,Brenda M. Sandmaier +6 more
Reads0
Chats0
TLDR
Although HCT professionals have not reached a consensus on what constitutes a RIC regimen, most accept currently used criteria and operational definitions, and these results support the continued use of current criteria for RIC regimens until a consensus statement can be developed.About:
This article is published in Biology of Blood and Marrow Transplantation.The article was published on 2009-03-01 and is currently open access. It has received 658 citations till now. The article focuses on the topics: Transplantation Conditioning & Transplantation.read more
Citations
More filters
Journal ArticleDOI
Defining the intensity of conditioning regimens: working definitions.
Andrea Bacigalupo,Karen K. Ballen,Doug Rizzo,Sergio Giralt,Hillard M. Lazarus,Vincent T. Ho,Jane F. Apperley,Shimon Slavin,Marcelo C. Pasquini,Brenda M. Sandmaier,John Barrett,Didier Blaise,Robert Lowski,Mary M. Horowitz +13 more
TL;DR: This report proposes to define conditioning regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity conditioning (RIC), and (3) nonmyeloablatives (NMA) Conditioning, based on the duration of cytopenia and on the requirement for stem cell support.
Journal ArticleDOI
Umbilical cord blood transplantation: the first 25 years and beyond
TL;DR: The results for adult umbilical cord blood transplantation have improved, with greater emphasis on cord blood units of sufficient cell dose and human leukocyte antigen match and with the use of double umbilicals Cord blood units and improved supportive care techniques.
Journal ArticleDOI
Hematopoietic stem cell transplantation: a global perspective
Alois Gratwohl,Helen Baldomero,Mahmoud Aljurf,Marcelo C. Pasquini,Luis Fernando Bouzas,Ayami Yoshimi,Jeff Szer,Jeffrey H. Lipton,Alvin Schwendener,Michael Gratwohl,Karl Frauendorfer,Dietger Niederwieser,Mary M. Horowitz,Yoshihisa Kodera,Marrow Transplantation +14 more
TL;DR: Hematopoietic stem cell transplantation is used for a broad spectrum of indications worldwide, but most frequently in countries with higher gross national incomes, higher governmental health care expenditures, and higher team densities.
Journal ArticleDOI
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea,Mei-Jie Zhang,Andrea Bacigalupo,Asad Bashey,Frederick R. Appelbaum,Omar S. Aljitawi,Philippe Armand,Joseph H. Antin,Junfang Chen,Steven M. Devine,Daniel H. Fowler,Leo Luznik,Ryotaro Nakamura,Paul O'Donnell,Miguel-Angel Perales,Sai Ravi Pingali,David L. Porter,Marcie L. Riches,Olle Ringdén,Vanderson Rocha,Ravi Vij,Daniel J. Weisdorf,Richard E. Champlin,Mary M. Horowitz,Ephraim J. Fuchs,Mary Eapen +25 more
TL;DR: It is suggested that survival for patients with AML after haploidentical transplantation with posttransplant cyclophosphamide is comparable with matched unrelated donor transplantation.
Journal ArticleDOI
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Madan Jagasia,Mukta Arora,Mary E.D. Flowers,Nelson J. Chao,Philip L. McCarthy,Corey Cutler,Alvaro Urbano-Ispizua,Steven Z. Pavletic,Michael Haagenson,Mei-Jie Zhang,Joseph H. Antin,Brian J. Bolwell,Christopher Bredeson,Jean-Yves Cahn,Mitchell S. Cairo,Robert Peter Gale,Vikas Gupta,Stephanie J. Lee,Mark R. Litzow,Daniel J. Weisdorf,Mary M. Horowitz,Theresa Hahn +21 more
TL;DR: Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.
References
More filters
Journal ArticleDOI
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
Shimon Slavin,Arnon Nagler,Ella Naparstek,Yossi Kapelushnik,Memet Aker,Gabriel Cividalli,G. Varadi,Mark Kirschbaum,Aliza Ackerstein,Simcha Samuel,Avraham Amar,Chaim Brautbar,Ofira Ben-Tal,Amiram Eldor,Reuven Or +14 more
TL;DR: Preliminary data in 26 patients with standard indications for allogeneic BMT suggest that nonmyeloablative conditioning including fludarabine, anti-T-lymphocyte globulin, and low-dose busulfan is extremely well tolerated, with no severe procedure-related toxicity.
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Issa F. Khouri,Michael J. Keating,M. Korbling,Donna Przepiorka,Paolo Anderlini,Susan O'Brien,Sergio Giralt,Cindy Ippoliti,B. Von Wolff,James Gajewski,M. Donato,David F. Claxton,Naoto T. Ueno,Borje S. Andersson,Adrian P. Gee,Richard E. Champlin +15 more
TL;DR: The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate-grade lymphoma is direct evidence of GVL activity against lymphoid malignancies.
Journal ArticleDOI
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
R Chopra,Annabel McMillan,D. C. Linch,S Yuklea,Goli Taghipour,Rachel Pearce,Keith G. Patterson,Ah Goldstone +7 more
TL;DR: Comparisons are made between high-dose chemotherapy with ABMT and conventional dose salvage therapy and patients with bulk, heavily pretreated patients (those receiving three or more lines of treatment) and females had a significantly poorer prognosis.
Journal ArticleDOI
Long-Term Follow-Up of a Randomized Trial of Two Irradiation Regimens for Patients Receiving Allogeneic Marrow Transplants During First Remission of Acute Myeloid Leukemia
TL;DR: A randomized trial of two irradiation regimens used to treat patients with acute myeloid leukemia in first remission by allogeneic marrow transplantation found one to be more effective than the other.
Related Papers (5)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report
Madan Jagasia,Hildegard T. Greinix,Mukta Arora,Kirsten M. Williams,Daniel Wolff,Edward W. Cowen,Jeanne Palmer,Daniel J. Weisdorf,Nathaniel S. Treister,Guang-Shing Cheng,Holly Kerr,Pamela Stratton,Rafael F. Duarte,George B. McDonald,Yoshihiro Inamoto,Afonso Celso Vigorito,Sally Arai,Manuel B. Datiles,David A. Jacobsohn,Theo Heller,Carrie L. Kitko,Sandra A. Mitchell,Paul J. Martin,Howard M. Shulman,Roy S. Wu,Corey Cutler,Georgia B. Vogelsang,Stephanie J. Lee,Steven Z. Pavletic,Mary E.D. Flowers +29 more